WORKATO
Workato , the leading enterprise automation platform, has today launched its first EMEA data centre in Frankfurt, Germany. The new data centre has been set up in response to exceptionally strong growth in the EMEA region, the company has seen a 289% increase in data usage on its platform from EMEA in the last 12 months. The launch of the data centre is part of the company’s strategy to boost investment twofold in the region and will provide Workato customers with a centralised location for hosting their data and provide assurance that their data residency requirements including GDPR are fully compliant and that their data is secure and protected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504006038/en/
The opening of the data centre in Frankfurt is testament to the strong demand Workato is seeing from European enterprises for its integration-led automation.
Workato supports customers throughout EMEA with operations currently in Spain, UK, Germany, France, Ireland, Netherlands and Italy. In January this year, the company announced Series D funding worth $110 million to be used to invest in developing its technology and expanding product innovation to help more companies around the world transform the way they work. Workato’s current customer base comprises of companies from the tech, financial services and fintech, transport and logistics, ecommerce and retail industries and include TFG Transfracht (Deutsche Bahn Group), Box, World Economic Forum (WEF), Showpad, Jumia and WorldRemit. As part of the company’s mission to improve the way enterprises work, Workato forms strategic partnerships with organisations such as Deloitte.
Markus Zirn, SVP of Strategy & Business Development at Workato commented: “The pandemic saw digital transformation catapulted to the top priority for enterprises. With increased focus on digital strategies and remote working, EMEA enterprises quickly recognised the need for automation platforms like Workato to achieve automation at scale by easily, reliably, and securely connecting applications, data, and business processes so teams can work smarter and faster.”
He added: “In response to this very strong demand for our technology across EMEA, we have invested in this new data centre, serving our European customers to ensuring their data is held in full compliance with new EU-data regulations, eliminating any risk and allowing us to help more and more businesses within the EU transform the way they work. We are delighted to be investing in this very important region for Workato and to be expanding our operations in EMEA.”
Workato customer, Agatha Sick, Head of IT at TFG Transfracht said: "Workato is enabling us to automate workflows across our enterprise.” She continued, “We are excited about the launch of the data centre in Europe as this will provide us with the option to store our data in the EU and comply with the EU data protection regulations."
Mark Watson, Chief Technology Officer at WorldRemit , another Workato customer added: “Workato’s powerful low-code/no-code integration and automation platform is enabling us to achieve automation at scale. We are excited about the launch of Workato’s Data Center in the European Union as it will enable us to keep our data close to home.”
Workato allows companies to maximise the value of their apps, data and people by making it easy to integrate disconnected data and applications, and securely automate workflows to accelerate business outcomes. Workato’s no code/low code platform combines enterprise-grade integration and automation capabilities in a single platform that is trusted by IT and easy to use for the business. With Workato, IT and business teams can more easily collaborate to rapidly integrate data, processes, applications and user experiences in almost any combination without compromising security and governance.
About Workato
Workato is the leading Enterprise Automation Platform. Recognised as a leader, Workato is the only enterprise platform that enables both business and IT to integrate their apps, automate business workflows, and drive real time outcomes from business events, without compromising security and governance. Workato is trusted by over 7,000 of the world’s top brands and fastest growing innovators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504006038/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom